Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25834431 | 0.92 | MMP2 (0.46) | USP2CRBNDDB1MMP2MMP9 | |
| SCHEMBL25834433 | 0.89 | MMP2 (0.49) | MMP2MMP9MMP13MMP14 | |
| SCHEMBL25834391 | 0.86 | CRBN (0.45) | CRBNDDB1MMP2MMP9MMP13 | |
| SCHEMBL5742870 | 0.85 | CRBN (0.59) | USP2CRBNDDB1 | |
| SCHEMBL25834450 | 0.84 | KMT2A (0.47) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL25834086 | 0.84 | CRBN (0.47) | CRBNDDB1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL25834074 | 0.83 | MEN1 (0.55) | CRBNMMP2MMP9MMP13 | |
| SCHEMBL25834087 | 0.81 | CRBN (0.41) | USP2CRBNDDB1ALDH1A1 | |
| SCHEMBL25834073 | 0.81 | CA2 (0.48) | CRBNMMP2MMP9MMP13ALDH1A1 | |
| SCHEMBL25834075 | 0.80 | CRBN (0.36) | CRBNDDB1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | USP2 701/4885CRBN 2/4885DDB1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.